Ph2 Study NKT2152 With Palbociclib & Sasanlimab in Subjects With Advanced Clear Cell Renal Cell Carcinoma (ccRcc)
NiKang Therapeutics, Inc.
NiKang Therapeutics, Inc.
Promontory Therapeutics Inc.
Catalysis SL
NanOlogy, LLC
Celldex Therapeutics
NanOlogy, LLC
Novartis
Dendreon
Pierre Fabre Medicament
Eli Lilly and Company
Pharmacyclics LLC.